Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 306, Issue 9, 2014, Pages

  Meng, Fanyin ^a,b,c   DeMorrow, Sharon ^b,c   Venter, Julie ^c   Frampton, Gabriel ^c   Han, Yuyan ^c   Francis, Heather ^a,b,c   Standeford, Holly ^a   Avila, Shanika ^c   McDaniel, Kelly ^a,b,c   McMillin, Matthew ^c   Afroze, Syeda ^c   Guerrier, Micheleine ^c   Quezada, Morgan ^b   Ray, Debolina ^c   Kennedy, Lindsey ^b   Hargrove, Laura ^b   Glaser, Shannon ^a,b,c   Alpini, Gianfranco ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Autocrine; Biliary cancer; Neuroendocrine; Sensory innervation; VEGF

Indexed keywords

3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; CYCLINE; CYTOKERATIN 19; MEMBRANE METALLOENDOPEPTIDASE; NEUROKININ 1 RECEPTOR; PROTEIN; PROTEIN TAC1; SUBSTANCE P; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BALB/C NUDE MOUSE; BILE DUCT CARCINOMA; CELL PROLIFERATION; CHOLANGIOCARCINOMA CELL LINE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

AUTOCRINE; BILIARY CANCER; NEUROENDOCRINE; SENSORY INNERVATION; VEGF;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-19; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEPRILYSIN; NEUROKININ-1 RECEPTOR ANTAGONISTS; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTORS, NEUROKININ-1; SUBSTANCE P; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900554657     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00018.2014     Document Type: Article

References (55)

1. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martin JD, Candenas ML. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 11: 2045-2081, 2004.
2. Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D, Lee SP, Marzioni M, Benedetti A, DeMorrow S. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 68: 9184-9193, 2008.
3. Alvaro D, Mancino MG, Glaser S, Gaudio E, Marzioni M, Francis H, Alpini G. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 132: 415-431, 2007.
4. Bang R, Biburger M, Neuhuber WL, Tiegs G. Neurokinin-1 receptor antagonists protect mice from CD95-and tumor necrosis factor-alphamediated apoptotic liver damage. J Pharmacol Exp Ther 308: 1174-1180, 2004.
5. Barrett KG, Fang H, Gargano MD, Markovich D, Kocarek TA, Runge-Morris M. Regulation of murine hepatic hydroxysteroid sulfotransferase expression in hyposulfatemic mice and in a cell model of 3′-phosphoadenosine-5′-phosphosulfate deficiency. Drug Metab Dispos 41: 1505-1513, 2013.
6. Berger H, Fechner K, Albrecht E, Niedrich H. Substance P: in vitro inactivation by rat brain fractions and human plasma. Biochem Pharmacol 28: 3173-3180, 1979.
7. Borscheri N, Roessner A, Rocken C. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol 25: 1297-1303, 2001.
8. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, Gaudio E, Alvaro D. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer 1: 21-32, 2012.
9. Castagliuolo I, Valenick L, Liu J, Pothoulakis C. Epidermal growth factor receptor transactivation mediates substance P induced mitogenic responses in U-373 MG cells. J Biol Chem 275: 26545-26550, 2000.
10. Cherry-Bohannan J, Baker K, Francis H. VEGF and cholangiocarcinoma: feeding the tumor. Transl Gastrointest Cancer 1: 95-102, 2012.
11. Davidson S, Miller KA, Dowell A, Gildea A, Mackenzie A. A remote and highly conserved enhancer supports amygdala specific expression of the gene encoding the anxiogenic neuropeptide substance-P. Mol Psychiatry 11: 410-421, 2006.
12. Deniz K, Coban G, Okten T. Anti-CD10 (56C6) expression in soft tissue sarcomas. Pathol Res Pract 208: 281-285, 2012.
13. Feng F, Yang J, Tong L, Yuan S, Tian Y, Hong L, Wang W, Zhang H. Substance P immunoreactive nerve fibres are related to gastric cancer differentiation status and could promote proliferation and migration of gastric cancer cells. Cell Biol Int 35: 623-629, 2011.
14. Francis H, DeMorrow S, Venter J, Onori P, White M, Gaudio E, Francis T, Greene JF Jr, Tran S, Meininger CJ, Alpini G. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 61: 753-764, 2012.
15. Francis H, Onori P, Gaudio E, Franchitto A, DeMorrow S, Venter J, Kopriva S, Carpino G, Mancinelli R, White M, Meng F, Vetuschi A, Sferra R, Alpini G. H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo. Mol Cancer Res 7: 1704-1713, 2009.
16. Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes H, Engel P, Costamagna D, Fernandez PL, Gascon P, Almendro V. Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res 73: 6424-6434, 2013.
17. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Franchitto A, Onori P, Ueno Y, Marzioni M, Fava G, Venter J, Reichenbach R, Summers R, Alpini G. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol 291: G307-G317, 2006.
18. Gaudio E, Barbaro B, Alvaro D, Glaser S, Francis H, Ueno Y, Meininger CJ, Franchitto A, Onori P, Marzioni M, Taffetani S, Fava G, Stoica G, Venter J, Reichenbach R, De Morrow S, Summers R, Alpini G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 130: 1270-1282, 2006.
19. Glaser S, Gaudio E, Renzi A, Mancinelli R, Ueno Y, Venter J, White M, Kopriva S, Chiasson V, DeMorrow S, Francis H, Meng F, Marzioni M, Franchitto A, Alvaro D, Supowit S, DiPette DJ, Onori P, Alpini G. Knockout of the neurokinin-1 receptor reduces cholangiocyte proliferation in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 301: G297-G305, 2011.
20. Glaser S, Ueno Y, DeMorrow S, Chiasson VL, Katki KA, Venter J, Francis HL, Dickerson IM, DiPette DJ, Supowit SC, Alpini G. Knockout of alpha-calcitonin gene-related peptide reduces cholangiocyte proliferation in bile duct ligated mice. Lab Invest 87: 914-926, 2007.
21. Gurel D, Kargi A, Karaman I, Onen A, Unlu M. CD10 expression in epithelial and stromal cells of nonsmall cell lung carcinoma (NSCLC): a clinic and pathologic correlation. Pathol Oncol Res 18: 153-160, 2012.
22. Han Y, DeMorrow S, Invernizzi P, Jing Q, Glaser S, Renzi A, Meng F, Venter J, Bernuzzi F, White M, Francis H, Lleo A, Marzioni M, Onori P, Alvaro D, Torzilli G, Gaudio E, Alpini G. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 301: G623-G633, 2011.
23. Hirano K, Nimura S, Mizoguchi M, Hamada Y, Yamashita Y, Iwasaki H. Early colorectal carcinomas: CD10 expression, mucin phenotype and submucosal invasion. Pathol Int 62: 600-611, 2012.
24. Holzer P. Efferent-like roles of afferent neurons in the gut: blood flow regulation and tissue protection. Auton Neurosci 125: 70-75, 2006.
25. Huang L, Frampton G, Rao A, Zhang KS, Chen W, Lai JM, Yin XY, Walker K, Culbreath B, Leyva-Illades D, Quinn M, McMillin M, Bradley M, Liang LJ, DeMorrow S. Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest 92: 1451-1460, 2012.
26. Jang TJ. CD10 is again expressed at a certain stage during the neoplastic process of bladder transitional cell carcinomas. Cancer Res Treat 44: 262-266, 2012.
27. 2+-dependent protein kinase C-alpha. J Hepatol 34: 284-291, 2001.
28. Kanno N, LeSage G, Glaser S, Alvaro D, Alpini G. Functional heterogeneity of the intrahepatic biliary epithelium. Hepatology 31: 555-561, 2000.
29. Kant V, Gopal A, Kumar D, Bag S, Kurade NP, Kumar A, Tandan SK, Kumar D. Topically applied substance P enhanced healing of open excision wound in rats. Eur J Pharmacol 715: 345-353, 2013.
30. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Meyer zum Buschenfelde KH. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1: 579-596, 1985.
31. Koon HW, Zhao D, Zhan Y, Moyer MP, Pothoulakis C. Substance P mediates antiapoptotic responses in human colonocytes by Akt activation. Proc Natl Acad Sci USA 104: 2013-2018, 2007.
32. Kusaka Y, Tokiwa T, Sato J. Establishment and characterization of a cell line from a human cholangiocellular carcinoma. Res Exp Med (Berl) 188: 367-375, 1988.
33. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 128: 1655-1667, 2005.
34. Li X, Ma G, Ma Q, Li W, Liu J, Han L, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E. Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol Cancer Res 11: 294-302, 2013.
35. Linnik MD, Moskowitz MA. Identification of immunoreactive substance P in human and other mammalian endothelial cells. Peptides 10: 957-962, 1989.
36. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 45: 856-867, 2006.
37. Munoz M, Rosso M, Aguilar FJ, Gonzalez-Moles MA, Redondo M, Esteban F. NK-1 receptor antagonists induce apoptosis and counteract substance P related mitogenesis in human laryngeal cancer cell line HEp-2. Invest New Drugs 26: 111-118, 2008.
38. Nakamura T. Changes in expression of bile canalicular CD10 and sinusoidal CD105 (endoglin) in peritumoral hepatic tissue. Tumori 95: 495-500, 2009.
39. Palma C. Tachykinins and their receptors in human malignancies. Curr Drug Targets 7: 1043-1052, 2006.
40. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2: 10, 2002.
41. Renzi A, Glaser S, DeMorrow S, Mancinelli R, Meng F, Franchitto A, Venter J, White M, Francis H, Han Y, Alvaro D, Gaudio E, Carpino G, Ueno Y, Onori P, Alpini G. Melatonin inhibits cholangiocyte hyperplasia in cholestatic rats by interaction with MT1 but not MT2 melatonin receptors. Am J Physiol Gastrointest Liver Physiol 301: G634-G643, 2011.
42. Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med 177: 61-71, 1995.
43. Sawchenko PE, Friedman MI. Sensory functions of the liver-a review. Am J Physiol Regul Integr Comp Physiol 236: R5-R20, 1979.
44. Schmitz KJ, Lang H, Wohlschlaeger J, Sotiropoulos GC, Reis H, Schmid KW, Baba HA. AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma. World J Gastroenterol 13: 6470-6477, 2007.
45. 2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol 317: 129-135, 1996.
46. Seiler R, von Gunten M, Thalmann GN, Fleischmann A. High CD10 expression predicts favorable outcome in surgically treated lymph nodepositive bladder cancer patients. Hum Pathol 43: 269-275, 2012.
47. Skidgel RA, Engelbrecht S, Johnson AR, Erdos EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides 5: 769-776, 1984.
48. Thomas-Pfaab M, Annereau JP, Munsch C, Guilbaud N, Garrido I, Paul C, Brousset P, Lamant L, Meyer N. CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. J Dermatol Sci 69: 105-113, 2013.
49. Tretiakova M, Antic T, Westerhoff M, Mueller J, Himmelfarb EA, Wang HL, Xiao SY. Diagnostic utility of CD10 in benign and malignant extrahepatic bile duct lesions. Am J Surg Pathol 36: 101-108, 2012.
50. Trivedi M, Bergasa NV. Serum concentrations of substance P in cholestasis. Ann Hepatol 9: 177-180, 2010.
51. Uyama N, Geerts A, Reynaert H. Neural connections between the hypothalamus and the liver. Anat Rec A Discov Mol Cell Evol Biol 280: 808-820, 2004.
52. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF-β-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 285: G31-G36, 2003.
53. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther 3: 299-307, 2004.
54. Yamaguchi K, Richardson MD, Bigner DD, Kwatra MM. Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. Cancer Chemother Pharmacol 56: 585-593, 2005.
55. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology 122: 985-993, 2002.